Literature DB >> 8878456

Interleukin-6 and granulocyte colony-stimulating factor synergistically increase peripheral blood progenitor cells in myelosuppressive mice.

H Suzuki1, A Okano, C Ejima, A Konishi, Y Akiyama, K Ozawa, S Asano.   

Abstract

We previously reported a successful peripheral blood stem cell harvest by co-administration of recombinant human (rh) interleukin-6 (IL-6) and rh granulocyte colony-stimulating factor (G-CSF) in normal mice. In the present study, to evaluate further the utility of this observation for autologous peripheral blood stem cell transplantation, we examined the effects of rhIL-6 and rhG-CSF on peripheral blood granulocyte-macrophage colony-forming units (CFU-GM) in carboplatin (CBDCA)-induced and irradiation-induced myelosuppressive mouse models. After CBDCA administration, blood cell counts decreased to the nadir, and then recovered to a normal level. In this recovery phase, the peripheral CFU-GM level increased to 3.8-fold higher than the pretreatment level. Administration of rhIL-6 (10 microgram/day) alone induced a 40-fold increase in peripheral CFU-GM from the normal level at day 14. In combination with rhG-CSF (0.35 microgram/day), which alone induced a 74-fold increase, rhIL-6 synergistically increased the CFU-GM level by 1200-fold. In irradiated mice, similar results were observed. Administration of rhIL-6 at 3 and 10 microgram/day significantly increased CFU-GM. Interestingly, in combination with rhG-CSF, a lower dose of rhIL-6 (1 microg/day) could induce CFU-GM increase. We also examined CFU-GM distribution in bone marrow, spleen and peripheral blood. Cytokine administration induced not only a change of CFU-GM distribution, but also an increase in total CFU-GM counts per mouse. These results suggest that co-administration of rhIL-6 and rhG-CSF may be useful for autologous peripheral blood stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878456      PMCID: PMC5921208          DOI: 10.1111/j.1349-7006.1996.tb02123.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  28 in total

1.  Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates.

Authors:  R G Andrews; R A Briddell; G H Knitter; S D Rowley; F R Appelbaum; I K McNiece
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113

2.  In vitro expansion of the murine pluripotent hemopoietic stem cell population in response to interleukin 3 and interleukin 6. Application to bone marrow transplantation.

Authors:  A Okano; C Suzuki; F Takatsuki; Y Akiyama; K Koike; K Ozawa; T Hirano; T Kishimoto; T Nakahata; S Asano
Journal:  Transplantation       Date:  1989-09       Impact factor: 4.939

3.  Increased numbers of circulating haematopoietic progenitor cells after treatment with high-dose interleukin-2 in cancer patients.

Authors:  M R Schaafsma; W E Fibbe; D van der Harst; N Duinkerken; A Brand; S Osanto; C R Franks; R Willemze; J H Falkenburg
Journal:  Br J Haematol       Date:  1990-10       Impact factor: 6.998

4.  Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.

Authors:  S Hohaus; H Goldschmidt; R Ehrhardt; R Haas
Journal:  Exp Hematol       Date:  1993-04       Impact factor: 3.084

5.  Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.

Authors:  A D Elias; L Ayash; K C Anderson; M Hunt; C Wheeler; G Schwartz; I Tepler; R Mazanet; C Lynch; S Pap
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

6.  Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin.

Authors:  W Brugger; K Bross; J Frisch; P Dern; B Weber; R Mertelsmann; L Kanz
Journal:  Blood       Date:  1992-03-01       Impact factor: 22.113

7.  Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy.

Authors:  F Kimura; Y Takemura; T Ohtsuki; H Mizukami; S Takagi; K Yamamoto; N Nagata; K Motoyoshi
Journal:  Int J Hematol       Date:  1992-04       Impact factor: 2.490

8.  High-level direct expression of semi-synthetic human interleukin-6 in Escherichia coli and production of N-terminus met-free product.

Authors:  H Yasueda; K Nagase; A Hosoda; Y Akiyama; K Yamada
Journal:  Biotechnology (N Y)       Date:  1990-11

9.  Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation.

Authors:  R Haas; G Gericke; B Witt; S Cayeux; W Hunstein
Journal:  Exp Hematol       Date:  1993-01       Impact factor: 3.084

10.  Effects of progenitor cell dose and preleukapheresis use of human recombinant granulocyte colony-stimulating factor on the recovery of hematopoiesis after blood stem cell autografting in children.

Authors:  Y Kawano; Y Takaue; T Watanabe; S Saito; T Abe; A Hirao; J Sato; T Ninomiya; T Suzue; T Koyama
Journal:  Exp Hematol       Date:  1993-01       Impact factor: 3.084

View more
  1 in total

1.  Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is critical for granulopoiesis.

Authors:  P Zhang; A Iwama; M W Datta; G J Darlington; D C Link; D G Tenen
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.